FDA Threatens China and India Fish Companies With Import Refusal, Reinspection Fees
The Food and Drug Administration recently sent warning letters to seafood companies in India and China, threatening refusal of their products at the border unless violations of the seafood hazard analysis and critical control point (HACCP) regulations are corrected. In a letter dated Jan. 16 (here), FDA warned Gadre Marine Export Pvt. Ltd. that deficient HACCP procedures at the company’s Gujarat, India facility rendered the company’s frozen imitation crab sticks adulterated under FDA regulations. In a letter dated Jan. 15 (here), FDA told Yuet Heung Yuen Sauce Food (Zhuhai) Ltd. that it considered oyster sauce produced at the company’s Zhuhai City, China facility to be adulterated, also because of HACCP violations.
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
FDA said both company’s fish products may be put on import alert and denied at the border without physical examination unless the HACCP violations are corrected. The agency also said it will conduct reinspections of each facility to verify compliance. Because each company’s violations are related to food safety, FDA will charge reinspection fees to each company’s U.S. agent, it said.